CTLA4 and prostate cancer: There has been limited benefit observed in prostate cancer through the unselected use of novel immune checkpoint inhibitors based on T cell receptor blockade (e.g., PD-1, PD-L1 and CTLA-4) https://paperpile.com/c/BQQ95X/i6jgh [15].